2.50
Hdl Handle:
http://hdl.handle.net/2436/620904
Title:
Autoimmunity and COPD: clinical implications.
Authors:
Caramori, Gaetano; Ruggeri, Paolo; Di Stefano, Antonino; Mumby, Sharon; Girbino, Giuseppe; Adcock, Ian M; Kirkham, Paul
Abstract:
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the age of 80 years. COPD is characterized by an abnormal immune response in the lower airways and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular- and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and to cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD patients has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of COPD has been firmly established in man. As such the potential contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being investigated and represents an area of active research. Many drugs targeting autoimmune responses are already available and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes or progression of stable COPD is promising.
Citation:
Autoimmunity and COPD: clinical implications. 2017 Chest
Publisher:
Elsevier
Journal:
Chest
Issue Date:
7-Nov-2017
URI:
http://hdl.handle.net/2436/620904
DOI:
10.1016/j.chest.2017.10.033
PubMed ID:
29126842
Type:
Article
Language:
en
ISSN:
0012-3692
Appears in Collections:
School of Biomedical Sciences and Physiology

Full metadata record

DC FieldValue Language
dc.contributor.authorCaramori, Gaetanoen
dc.contributor.authorRuggeri, Paoloen
dc.contributor.authorDi Stefano, Antoninoen
dc.contributor.authorMumby, Sharonen
dc.contributor.authorGirbino, Giuseppeen
dc.contributor.authorAdcock, Ian Men
dc.contributor.authorKirkham, Paulen
dc.date.accessioned2017-11-28T12:01:23Z-
dc.date.available2017-11-28T12:01:23Z-
dc.date.issued2017-11-07-
dc.identifier.citationAutoimmunity and COPD: clinical implications. 2017 Chesten
dc.identifier.issn0012-3692en
dc.identifier.pmid29126842-
dc.identifier.doi10.1016/j.chest.2017.10.033-
dc.identifier.urihttp://hdl.handle.net/2436/620904-
dc.description.abstractChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Long term cigarette smoking is the cause of more than 90% of COPD in Westernized countries. However, only a fraction of chronic heavy smokers develop symptomatic COPD by the age of 80 years. COPD is characterized by an abnormal immune response in the lower airways and its progression is associated with infiltration of the lung by innate and adaptive inflammatory immune cells that form lymphoid follicles. There is growing evidence that both cellular- and antibody-mediated autoimmunity has a fundamental role in the pathogenesis of stable COPD. In particular, carbonyl-modified proteins may help to drive autoimmunity in COPD and to cause the characteristic small airways abnormalities and even contribute to the pathogenesis of pulmonary emphysema. Although direct, indirect, and circumstantial evidence of a role for autoimmunity in stable COPD patients has been identified, no cause-and-effect relationship between autoimmunity and the mechanisms of COPD has been firmly established in man. As such the potential contribution of an autoimmune response to the pathogenesis of COPD exacerbation is still being investigated and represents an area of active research. Many drugs targeting autoimmune responses are already available and the results of controlled clinical trials are awaited with great interest. The potential for measuring specific serum autoantibodies as biomarkers to predict clinical phenotypes or progression of stable COPD is promising.en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to Chesten
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectADCCen
dc.subjectBALTen
dc.subjectautoantibodyen
dc.subjectautoimmunityen
dc.subjectmAbsen
dc.titleAutoimmunity and COPD: clinical implications.en
dc.typeArticleen
dc.identifier.journalChesten
dc.date.accepted2017-10-27-
rioxxterms.funderinternalen
rioxxterms.identifier.projectUOW281117PKen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2018-11-07en

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.